Table 2.
Overview of CXCR4 antagonists that have been tested in various types of cancer for their therapeutic power/benefit.
| CXCR4 Antagonists | Type of Cancer | References |
|---|---|---|
| AMD3100 (plerixafor) |
Glioblastoma, breast cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, melanoma, AML, ALL, CML, MM, non- Hodgkin’s lymphoma, HSC mobilization | [55] |
| AMD3465 | AML, ALL, breast cancer | [55,56,57] |
| RCP168 | AML | [56] |
| PRX17756 | Glioblastoma | [52,53] |
| BL-8040 | Glioblastoma, MM | [54,58] |
| USL311 | Glioblastoma | (ClinicalTrials.gov identifier: NCT02765165), [59] |
| Balixafortide | Breast cancer | [60] |
| BKT140 | CML, MM | [55,61] |
| AMD070 | Oral cancer | [62] |
| LY2624587 | Non-Hodgkin’s lymphoma, ALL | [63] |
| T140 | CLL, ALL, MM, SCLC | [64,65,66] |
| TG-0054 | CLL, MM | [67] |
| POL6326 | CLL, MM | [67] |
| MSX-122 | CLL, MM, breast cancer | [67,68] |
| TC14012 | CLL | [64] |
| TN14003 | CLL | [64] |
| CTCE-9908 | Ovarian cancer, prostate cancer, esophageal cancer, breast cancer | [69,70,71,72] |
| CTCE-0021 | HSC mobilization | [73,74] |
| CTCE-0214 | HSC mobilization | [55] |
| ATI-2341 | HSC mobilization | [73] |
Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HSC, hematopoietic stem cell; MM, multiple myeloma; SCLC, small cell lung cancer.